These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26379984)

  • 21. Optical coherence tomography findings as a predictor of clinical course in patients with branch retinal vein occlusion treated with ranibizumab.
    Shiono A; Kogo J; Sasaki H; Yomoda R; Jujo T; Tokuda N; Kitaoka Y; Takagi H
    PLoS One; 2018; 13(6):e0199552. PubMed ID: 29924853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal bevacizumab for macular complications from retinal arterial macroaneurysms.
    Pichi F; Morara M; Torrazza C; Manzi G; Alkabes M; Balducci N; Vitale L; Lembo A; Ciardella AP; Nucci P
    Am J Ophthalmol; 2013 Feb; 155(2):287-294.e1. PubMed ID: 23111179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients.
    Yang X; Dai H
    Chin Med J (Engl); 2014; 127(16):2906-10. PubMed ID: 25131225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
    Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
    Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
    Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of one and three initial monthly intravitreal ranibizumab injection in patients with macular edema secondary to branch retinal vein occlusion.
    Bayat AH; Çakır A; Özturan ŞG; Bölükbaşı S; Erden B; Elçioğlu MN
    Int J Ophthalmol; 2018; 11(9):1534-1538. PubMed ID: 30225230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
    Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
    Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS FOR EXUDATIVE RETINAL ARTERIAL MACROANEURYSMS.
    Mansour AM; Foster RE; Gallego-Pinazo R; Moschos MM; Sisk RA; Chhablani J; Rojanaporn D; Sujirakul T; Arevalo JF; Lima LH; Wu L; Charbaji A; Saatci AO; Mansour HA; Martinez-Rubio C; Patel Y; Gangakhedkar S
    Retina; 2019 Jun; 39(6):1133-1141. PubMed ID: 29505440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of Underlying Causes of Spontaneous Submacular Hemorrhage by Indocyanine Green Angiography.
    Kim H; Lee SC; Kim SM; Lee JH; Koh HJ; Kim SS; Byeon SH; Kim M; Lee CS
    Ophthalmologica; 2015; 233(3-4):146-54. PubMed ID: 25833061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab.
    Massamba N; Dirani A; Knoeri J; Pasquier B; Ingram A; Soubrane G
    Eye (Lond); 2015 Nov; 29(11):1453-7. PubMed ID: 26206530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab.
    Calvo P; Ferreras A; Al Adel F; Wang Y; Brent MH
    Br J Ophthalmol; 2015 Jun; 99(6):723-6. PubMed ID: 25425713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of inner and outer retinal thickness in patients receiving intravitreal ranibizumab injections for diabetic macular edema.
    Dursun A; Ozec AV; Kirboga K; Dursun FG; Toker MI; Erdogan H; Arici MK
    Eur J Ophthalmol; 2016; 26(1):48-53. PubMed ID: 26220809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravitreal ranibizumab or conbercept for retinal arterial macroaneurysm: a case series.
    Lin Z; Hu Q; Wu Y; Xu J; Zhang Q
    BMC Ophthalmol; 2019 Jan; 19(1):18. PubMed ID: 30646868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results.
    Chevreaud O; Oubraham H; Cohen SY; Jung C; Blanco-Garavito R; Gherdaoui F; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):743-751. PubMed ID: 27913869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Macular cystic changes as predictive factor for the recurrence of macular oedema in branch retinal vein occlusion.
    Tilgner E; Dalcegio Favretto M; Tuisl M; Wiedemann P; Rehak M
    Acta Ophthalmol; 2017 Nov; 95(7):e592-e596. PubMed ID: 28266152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.